Santarus (SNTS) says an advanced study of its investigational antibiotic Rifamycin SV MMX met...

|By:, SA News Editor

Santarus (SNTS) says an advanced study of its investigational antibiotic Rifamycin SV MMX met its primary endpoint in treating travelers' diarrhea. Shares +4.3% AH.